Ostivea

Ostivea

ibandronic acid

Manufacturer:

UNAM Pharmaceutical

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Ibandronic acid
Indications/Uses
Postmenopausal osteoporosis to reduce risk of fractures.
Dosage/Direction for Use
3 mg IV inj over 15-30 sec every 3 mth.
Contraindications
Special Precautions
Discontinue use if anaphylactic or other severe hypersensitivity/allergic reactions occur. Not to be inj via intraarterial or paravenous administration. Delay treatment in patients w/ unhealed open soft tissue mouth lesions. Avoid overhydration in patients at risk of cardiac failure. Osteonecrosis of the jaw & external auditory canal; atypical subtrochanteric & diaphyseal femoral fractures. Correct existing hypocalcemia prior to therapy. Ensure adequate intake of Ca & vit D. Perform dental exam w/ preventive dentistry prior to treatment. Avoid invasive dental procedures & maintain good oral hygiene during treatment. Long-term therapy. Not recommended in patients w/ serum creatinine >200 micromol/L (2.3 mg/dL) or CrCl <30 mL/min. Not to be taken by women of childbearing potential. Not to be used during pregnancy & lactation. Not to be used in childn <18 yr.
Adverse Reactions
Headache; gastritis, dyspepsia, diarrhoea, abdominal pain, nausea, constipation; rash; arthralgia, myalgia, musculoskeletal & back pain; flu-like illness, fatigue.
Drug Interactions
Incompatibility w/ Ca-containing soln or other IV medicinal products.
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA06 - ibandronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Presentation/Packing
Form
Ostivea soln for inj 3 mg/3 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in